Verapamil
- Generic Name
- Verapamil
- Brand Names
- Calan, Isoptin, Tarka, Verelan
- Drug Type
- Small Molecule
- Chemical Formula
- C27H38N2O4
- CAS Number
- 52-53-9
- Unique Ingredient Identifier
- CJ0O37KU29
- Background
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like diltiazem and flunarizine, bu...
- Indication
Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter....
- Associated Conditions
- Chronic Stable Angina Pectoris, Cluster Headache, Heart Rate, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Supra-ventricular Tachyarrhythmias, Unstable Angina Pectoris, Vasospastic Angina
- Associated Therapies
- -
Is Verapamil In TransRadial Interventions OmittabLe?
- Conditions
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- State Health Center, Hungary
- Target Recruit Count
- 591
- Registration Number
- NCT01402427
- Locations
- 🇭🇺
State Health Center, Budapest, Hungary
Comparison of Medical Therapies in Marfan Syndrome.
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2011-02-14
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 18
- Registration Number
- NCT01295047
- Locations
- 🇬🇧
Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom
DDI Between BI Empagliflozin (10773) and Verapamil
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01276301
- Locations
- 🇩🇪
1245.43.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug-Disease Interaction in Crohn's Disease
- Conditions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT01261286
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2010-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01197781
- Locations
- 🇺🇸
Recruiting Site, Overland Park, Kansas, United States
Study of Verapamil in Refractory Epilepsy
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2010-05-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 16
- Registration Number
- NCT01126307
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Cluster Headache Cortivazol Injection (CHCI)
- Conditions
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 43
- Registration Number
- NCT00804895
- Locations
- 🇫🇷
CHU Lariboisière, AP-HP, Centre des Urgences Céphalées (Emergency Headacha Center), Paris, Ile de France, France
Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 102
- Registration Number
- NCT00712894
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
An Interaction Study of Ketoconazole/Verapamil Versus AZD1305
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00707551
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 8
- Registration Number
- NCT00706810
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.